Publication Name	World Journal of Clinical Oncology
Manuscript ID	83164
Country	United States

Received	2023-01-09 21:23
Peer-Review Started	2023-01-09 21:25
To Make the First Decision
Return for Revision	2023-01-31 08:53
Revised	2023-02-28 16:49
Second Decision	2023-04-21 03:02
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2023-04-21 08:03
Articles in Press	2023-04-21 08:03
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-05-11 09:16
Publish the Manuscript Online	2023-05-19 06:25

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
Manuscript Source	Invited Manuscript
All Author List	Aya Abunada, Zaid Sirhan, Anita Thyagarajan and Ravi P Sahu
Funding Agency and Grant Number	Funding Agency Grant Number Elsa U. Pardee Foundation grant 671432 NIH R21 grant ES033806
Corresponding Author	Ravi P Sahu, BSc, MSc, PhD, Assistant Professor, Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, 230 Health Sciences Bldg, 3640 Colonel Glenn Hwy, Dayton, OH 45435, United States. ravi.sahu@wright.edu
Key Words	Human epidermal growth factor receptor-2 positive breast cancer; Tyrosine kinase inhibitors; Lapatinib; Pyrotinib; Tucatinib; Trastuzumab
Core Tip	Newly published randomized controlled trials within the past two years have provided compelling evidence on the use of tyrosine kinase inhibitors (TKIs) such as Lapatinib, Pyrotinib, Neratinib, Tucatinib, Ruxolitinib, and Afatinib. Several of these agents were found to offer better outcomes in terms of progression-free survival when combined with other agents. While some TKIs, namely Lapatinib, and Neratinib, are supported with a large amount of data than others, the medical literature still lacks substantial evidence to draw a clinical conclusion that could modify/add to the present recommendations in human epidermal growth factor receptor-2 positive breast cancer treatment guidelines.
Publish Date	2023-05-19 06:25
Citation	Abunada A, Sirhan Z, Thyagarajan A, Sahu RP. Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer. World J Clin Oncol 2023; 14(5): 198-202
URL	https://www.wjgnet.com/2218-4333/full/v14/i5/198.htm
DOI	https://dx.doi.org/10.5306/wjco.v14.i5.198

Full Article (PDF)	WJCO-14-198.pdf
Full Article (Word)	WJCO-14-198.docx
Manuscript File	83164_Auto_Edited-JLW.docx
Answering Reviewers	83164-Answering reviewers.pdf
Audio Core Tip	83164-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	83164-Conflict-of-interest statement.pdf
Copyright License Agreement	83164-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	83164-Grant application form(s).pdf
Peer-review Report	83164-Peer-review(s).pdf
Scientific Misconduct Check	83164-Bing-Li L-2.png
Scientific Editor Work List	83164-Scientific editor work list.pdf
CrossCheck Report	83164-CrossCheck report.pdf
CrossCheck Report	83164-CrossCheck.png